Botulinum Toxin B

  title={Botulinum Toxin B},
  author={David P. Figgitt and Stuart Noble},
SummaryAbstractBotulinum toxins are well known as the causative agents of human botulism food poisoning. However, in the past two decades they have become an important therapeutic mainstay in the treatment of dystonias including cervical dystonia, a neurological disorder characterised by involuntary contractions of the cervical and/or shoulder muscles. The toxins inhibit acetylcholine release from neuromuscular junctions, producing muscle weakness when injected into dystonic muscles.Data from… 
5 Citations
Smell and taste in idiopathic blepharospasm
The pathophysiology of blepharospasm is incompletely understood. Current concepts suggest that blepharospasm is a network disorder, involving basal ganglia, thalamus, cortex, and, possibly, the
A Biopsychosocial Model-Based Clinical Approach in Myofascial Pain Syndrome: A Narrative Review
A holistic approach, which blends the basic clinical care with the management of the biopsychosocial model, is essential to patients with MPS to regain their function and improve their quality of life and wellbeing.
Passive Monoclonal and Polyclonal Antibody Therapies
The history of use of passive antibody therapies, their mechanism of action, pharmacologic-therapeutic classification, particular medical indication, adverse reactions, and potential future use of these medications are reviewed.
Ultrasound Imaging of Injections in Masseter Muscle without Contrast Agent Using Strain Elastography and a Novel B-Mode Spatiotemporal Filter.
The proposed methods contribute to objectivize ultrasound-guided injections, with additional applications, for instance, to monitor injectate spread of local anesthetics.


Botulinum toxin: from poison to remedy.
This review tries to outline in brief the characteristics of Botulinum toxins, their mechanism of action and the various indications for clinical use as a therapeutic agent.
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Improvements associated with BoNT/B treatment were greatest for patients who received the 10,000-U dose, and Botulinum toxin type B (NeuroBloc) is safe and efficacious at 5,000 U and 10, thousand U for the management of patients with cervical dystonia.
Development of resistance to botulinum toxin type A in patients with torticollis
It is recommended that physicians wait as long as possible between btx injections, avoid booster injections, and use the smallest possible doses, in order to minimize the risk of developing btx resistance.
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Botulinum toxin type B (BoNT/B) (NeuroBloc) is safe and efficacious for the management of patients with type A-resistant cervical dystonia with an estimated duration of treatment effect of 12 to 16 weeks.
Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
BotB is safe, well tolerated, and efficacious in the treatment of cervical dystonia at the doses tested and a statistically significant treatment effect and a dose response.
Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology.
Electrophysiologic studies in cynomolgus monkeys showed that botulinum toxin type B is effective in paralyzing injected muscle groups, with minimal spread to relatively distant noninjected muscles.
The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.
The results from the three controlled clinical trials demonstrate the safety and efficacy of BTX-B in the treatment of patients with CD, including those who are resistant toBTX-A treatment.
Botulinum toxin therapy, immunologic resistance, and problems with available materials
Limiting the dose to < or = 100 LD50 units per injection cycle may limit this complication in the interim and be a method to reduce antigen exposure and mitigate against immunoresistance associated with dystonia therapy.
Response and immunoresistance to botulinum toxin injections
There were no other factors that could reliably predict which patients would become immunoresistant to BTX type A injections and treatment with alternate serotypes may offer clinical benefit to this group of patients.
Therapeutic uses of botulinum toxin.
Botulinum toxin type A, one of the most lethal biologic toxins, has been found to be of therapeutic value in the treatment of a variety of neurologic and ophthalmologic disorders.